{
"@context": "https://schema.org",
"@graph": [
{
"@type": "WebPage",
"@id": "https://www.fortrea.com/insights/strategic-considerations-when-planning-externally-controlled-single-arm-trial#webpage",
"url": "https://www.fortrea.com/insights/strategic-considerations-when-planning-externally-controlled-single-arm-trial",
"name": "Strategic considerations when planning an externally controlled single-arm trial",
"description": "Explore this Fortrea white paper examining externally controlled single-arm trials and the increasing use of external control arms to support clinical development when randomized controlled trials may be impractical, infeasible, or difficult to conduct. The white paper explores FDA guidance related to externally controlled studies and discusses how real-world evidence derived from patient registries, electronic health records, healthcare claims data, and other data sources can be used to construct external comparator cohorts. It provides detailed insight into external control arm clinical trial design, including patient comparability, eligibility criteria alignment, control arm selection, study population matching, data quality assessment, and methodological considerations that influence the reliability of treatment effect estimates. The paper also evaluates historical, concurrent, and synthetic control arm approaches while examining bias mitigation strategies, confounding adjustment methods, and evidence-generation frameworks that can help sponsors strengthen study validity and support more robust clinical research outcomes through externally controlled single-arm trials."
},
{
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "Home",
"item": "https://www.fortrea.com"
},
{
"@type": "ListItem",
"position": 2,
"name": "Insights",
"item": "https://www.fortrea.com/insights/"
},
{
"@type": "ListItem",
"position": 3,
"name": "Strategic considerations when planning an externally controlled single-arm trial",
"item": "https://www.fortrea.com/insights/strategic-considerations-when-planning-externally-controlled-single-arm-trial"
}
]
},
{
"@type": "Organization",
"@id": "https://www.fortrea.com/#organization",
"name": "Fortrea",
"url": "https://www.fortrea.com",
"description": "Fortrea is a global contract research organization built on more than 30 years of experience and one of the earliest CRO legacies in the industry—as Covance, evolving within Labcorp, and now operating as Fortrea. With deep expertise across Phase I–IV clinical trials, Fortrea advances clinical research through a patient-centric approach that prioritizes meaningful outcomes, stronger site–CRO relationships, and operational excellence. Fortrea partners with biopharmaceutical, biotech, and medical device companies to advance therapies through every stage of clinical development. This commitment is further reinforced by the launch of Fortrea Intelligent Technology, enabling smarter, more connected, and data-driven clinical development. Through Fortrea Intelligent Technology, the organization is advancing data-driven, technology-enabled clinical development to improve speed, quality, and patient outcomes. It is shaped by experience, innovation, and a commitment to raising standards in clinical research—focused on accelerating development and helping bring life-changing treatments to patients around the world.",
"logo": "https://www.fortrea.com/sites/default/files/2025-05/fortrea-logo-without-background.png",
"sameAs": [
"https://www.linkedin.com/company/fortrea",
"https://www.threads.net/@fortreacro",
"https://twitter.com/fortrea",
"https://www.youtube.com/@Fortrea/",
"https://www.facebook.com/Fortrea-104143099267108",
"https://www.instagram.com/fortreacro"
]
},
{
"@type": "Article",
"@id": "https://www.fortrea.com/insights/strategic-considerations-when-planning-externally-controlled-single-arm-trial#whitepaper",
"mainEntityOfPage": {
"@id": "https://www.fortrea.com/insights/strategic-considerations-when-planning-externally-controlled-single-arm-trial#webpage"
},
"headline": "Strategic considerations when planning an externally controlled single-arm trial",
"description": "Explore this Fortrea white paper examining externally controlled single-arm trials and the increasing use of external control arms to support clinical development when randomized controlled trials may be impractical, infeasible, or difficult to conduct. The white paper explores FDA guidance related to externally controlled studies and discusses how real-world evidence derived from patient registries, electronic health records, healthcare claims data, and other data sources can be used to construct external comparator cohorts. It provides detailed insight into external control arm clinical trial design, including patient comparability, eligibility criteria alignment, control arm selection, study population matching, data quality assessment, and methodological considerations that influence the reliability of treatment effect estimates. The paper also evaluates historical, concurrent, and synthetic control arm approaches while examining bias mitigation strategies, confounding adjustment methods, and evidence-generation frameworks that can help sponsors strengthen study validity and support more robust clinical research outcomes through externally controlled single-arm trials.",
"genre": "White Paper",
"image": {
"@type": "ImageObject",
"url": "https://www.fortrea.com/sites/default/files/2025-02/externally-controlled-single-arm-trial.jpg"
},
"author": {
"@type": "Organization",
"name": "Fortrea",
"url": "https://www.fortrea.com/"
},
"publisher": {
"@id": "https://www.fortrea.com/#organization"
},
"datePublished": "2025-02-21",
"dateModified": "2025-02-21",
"encoding": {
"@type": "MediaObject",
"contentUrl": "https://www.fortrea.com/sites/default/files/2025-02/externally-controlled-single-arm-trial.pdf",
"encodingFormat": "application/pdf"
}
}
]
}